Energizing gene therapy; an AI newco; and Ono-Deciphera — a BioCentury podcast

FDA’s policies to overcome the barriers slowing gene therapy

Led by CBER Director Peter Marks, FDA is moving forward with policies that aim to improve access to gene therapies for patients with rare diseases. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how the agency plans to use regulatory policies to overcome barriers that are slowing gene therapy, as well as how Pfizer Inc. (NYSE:PFE) hopes to ensure access to hemophilia gene therapy Beqvez fidanacogene elaparvovec.

The editors also assess the $2.4 billion acquisition of Massachusetts oncology company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) by Japan’s Ono Pharmaceutical Co. Ltd. (Tokyo:4528) as it seeks to diversify its pipeline beyond PD-1 inhibitor Opdivo nivolumab and expand its global footprint. They also discuss the $1 billion launch of AI-guided therapeutics developer Xaira Therapeutics Inc.

Finally, BioCentury’s Joshua Berlin joins the podcast to preview BioCentury’s upcoming conference Bio€quity Europe, which kicks off May 12 in San Sebastián, Spain in Basque Country.

For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com.